Repligen Corporation (RGEN)
-NasdaqGS 8.85 
0.03(0.34%) May 17, 4:00PM EDT|After Hours
:
8.85 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 8.88 |
|---|
| Open: | 9.05 |
|---|
| Bid: | 8.51 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 12.00 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 8.75 - 9.10 |
|---|
| 52wk Range: | 3.72 - 9.65 |
|---|
| Volume: | 989,645 |
|---|
| Avg Vol (3m): | 292,425 |
|---|
| Market Cap: | 278.26M |
|---|
| P/E (ttm): | 18.51 |
|---|
| EPS (ttm): | 0.48 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- REPLIGEN CORP FinancialsEDGAR Online Financials(Tue, May 14)
- Repligen Stock Sees Short Interest Move 24.7% Higherat Forbes(Fri, May 10)
- REPLIGEN CORP Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 10)
- REPLIGEN CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
- Repligen's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 3)
- Repligen Corporation Earnings Call scheduled for 9:00 am ET todayCCBN(Thu, May 2)
- Repligen Reports First Quarter 2013 Financial ResultsGlobeNewswire(Thu, May 2)
- Q1 2013 Repligen Corporation Earnings Release - Before Market OpenCCBN(Thu, May 2)
- REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 2)
- Incremental Changes in Regulatory Environment Beneficial to Development-Stage Biotech Companies Due to Emphasis on Closer Working Relationships with the FDA and Drug SponsorsWall Street Transcript(Wed, May 1)
- Isis Pharma's ISIS-SMNRx ProgressesZacks(Wed, Apr 24)
- Repligen to Report First Quarter 2013 Financial ResultsGlobeNewswire(Tue, Apr 23)
- Repligen Promises To Be A Cash Flow Machineat Seeking Alpha(Tue, Apr 2)
- REPLIGEN CORP Files SEC form 10-K, Annual ReportEDGAR Online(Fri, Mar 15)
- Repligen Management Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Mar 7)
Key Statistics
| Forward P/E (1 yr): | 31.61 |
|---|
| P/S (ttm): | 4.24 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.56 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.10 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies worldwide.
View More